Chung, H. C., Arkenau, H., Lee, J., Rha, S. Y., Oh, D., Wyrwicz, L., Kang, Y., Lee, K., Infante, J. R., Lee, S. S., Kemeny, M., Keilholz, U., Melichar, B., Mita, A., Plummer, R., Smith, D., Gelb, A. B., Xiong, H., Hong, J., Chand, V., & Safran, H. (2019). avelumab (anti–PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial. Journal for immunotherapy of cancer, 7(1), . http://access.bl.uk/ark:/81055/vdc_100144514934.0x000019